US-based Moderna Therapeutics, which is currently valued at $5 billion, has developed its first vaccine from the cancer tissue of a 67-year-old that would train the patient's body to attack tumours. It took about 100 people to develop the single-use drug for one person. The vaccine is said to "hijack" cells' protein-making mechanisms to create a drug within the body.